Brokers Offer Predictions for Intercept Pharmaceuticals, Inc.’s FY2017 Earnings (ICPT)
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Stock analysts at Leerink Swann cut their FY2017 earnings estimates for shares of Intercept Pharmaceuticals in a research note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will post earnings of ($13.14) per share for the year, down from their previous estimate of ($13.05). Leerink Swann has a “Hold” rating and a $60.00 price objective on the stock. Leerink Swann also issued estimates for Intercept Pharmaceuticals’ Q4 2017 earnings at ($3.21) EPS, Q1 2018 earnings at ($3.71) EPS, Q2 2018 earnings at ($4.12) EPS, Q3 2018 earnings at ($4.63) EPS, Q4 2018 earnings at ($5.23) EPS, FY2018 earnings at ($17.73) EPS, FY2019 earnings at ($11.32) EPS and FY2020 earnings at ($11.95) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The business had revenue of $41.33 million for the quarter, compared to analyst estimates of $36.95 million. During the same quarter last year, the business earned ($3.59) earnings per share. The company’s revenue for the quarter was up 697.9% compared to the same quarter last year.
A number of other research firms have also weighed in on ICPT. Cowen restated an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. Goldman Sachs Group restated a “neutral” rating and set a $79.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, October 6th. Cantor Fitzgerald restated an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $144.13.
Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $61.21 on Thursday. Intercept Pharmaceuticals has a 52-week low of $54.98 and a 52-week high of $135.59. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 2,566 shares of company stock worth $151,025 over the last ninety days. 9.20% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Public Employees Retirement Association of Colorado raised its stake in Intercept Pharmaceuticals by 1.1% during the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 43 shares during the period. Janney Montgomery Scott LLC raised its stake in Intercept Pharmaceuticals by 1.8% during the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after purchasing an additional 62 shares during the period. WFG Advisors LP raised its stake in Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 125 shares during the period. Utah Retirement Systems raised its stake in shares of Intercept Pharmaceuticals by 6.5% in the 2nd quarter. Utah Retirement Systems now owns 3,300 shares of the biopharmaceutical company’s stock valued at $400,000 after acquiring an additional 200 shares during the period. Finally, State of Wisconsin Investment Board raised its stake in shares of Intercept Pharmaceuticals by 7.9% in the 2nd quarter. State of Wisconsin Investment Board now owns 3,567 shares of the biopharmaceutical company’s stock valued at $432,000 after acquiring an additional 260 shares during the period. 73.79% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/02/brokers-offer-predictions-for-intercept-pharmaceuticals-inc-s-fy2017-earnings-icpt-2.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.